Lupron has been used for premanopausal metastatic breast cancer where there are few other hormonal therapy options (except tamoxifen) for over two decades with most studies clustered in the 1980s and 1990s. It is NCCN Compendia recommended. Most studies used it along with other hormonal treatments but it has also been well supported alone.
Many clinicians currently recommend that leuprolide be limited to use in pre-menopausal women with breast cancer.NCCN 2011 recommends it on p. MS-39 (p.102)
NCCN Drugs & Biologics Compendium™. Leuprolide acetate. Copyright 2009, National Comprehensive Cancer Network (NCCN).
Gnant, Michael, Mlineritsch, Brigitte, Schippinger, Walter, Luschin-Ebengreuth, Gero, Postlberger, Sabine, Menzel, Christian, Jakesz, Raimund, Seifert, Michael, Hubalek, Michael, Bjelic-Radisic, Vesna, Samonigg, Hellmut, Tausch, Christoph, Eidtmann, Holger, Steger, Gunther, Kwasny, Werner, Dubsky, Peter, Fridrik, Michael, Fitzal, Florian, Stierer, Michael, Rucklinger, Ernst, Greil, Richard, the ABCSG-12 Trial Investigators, Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer N Engl J Med 2009 360: 679-691
Cancer of the breast. EBM (evidence-based medicine) guidelines. Available online at http://www.ebm-guidelines.com/. Helsinki, Finland: Duodecim Medical Publications Ltd, January 4, 2001:1-6.
nccn.org, breast 2014
Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reproduct Biol. 2007;134:3-8.